{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:56:55Z","timestamp":1775552215332,"version":"3.50.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["Off Road; 04510012210034"],"award-info":[{"award-number":["Off Road; 04510012210034"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>We summarise the current knowledge of T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) across innate and adaptive immune cells and compile emerging evidence in cardiovascular disease (CVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Immune checkpoints have come to light as potent regulators of immune responses in tumour biology, autoimmune disease and, more recently, in CVD. TIM-3 is a complex immune checkpoint expressed on both immune and non-immune cells. It has four known ligands, two of which are only available for binding upon cell damage or death, and binding can be either stimulatory or inhibitory. It functions as a context-dependent modulator of immune reactions in atherosclerosis, myocardial infarction and myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>TIM-3 may exert functions in the cardiovascular system, but more mechanistic research is required to investigate whether interference with TIM-3 signalling can be used to improve cardiovascular health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-026-00755-y","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:08:24Z","timestamp":1775549304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TIM-3 in Cardiovascular Disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Laura I.","family":"Yousif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aukje G.","family":"Sijtema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot J.","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3287-6766","authenticated-orcid":false,"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1161\/CIRCRESAHA.123.323656","volume":"134","author":"DL Mann","year":"2024","unstructured":"Mann DL. The emerging field of cardioimmunology: past, present and foreseeable future. Circ Res. 2024;134:1663\u201380. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.323656.","journal-title":"Circ Res"},{"key":"755_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550226","volume":"16","author":"B Mo","year":"2025","unstructured":"Mo B, Ding Y, Ji Q. NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol. 2025;16:1550226. https:\/\/doi.org\/10.3389\/fimmu.2025.1550226.","journal-title":"Front Immunol"},{"key":"755_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01183-2","volume":"8","author":"K Wang","year":"2022","unstructured":"Wang K, Chen X-Z, Wang Y-H, Cheng X-L, Zhao Y, Zhou L-Y. Emerging roles of ferroptosis in cardiovascular diseases. Cell Death Discov. 2022;8:394. https:\/\/doi.org\/10.1038\/s41420-022-01183-2.","journal-title":"Cell Death Discov"},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (1979). 1996;271:1734\u20136. https:\/\/doi.org\/10.1126\/science.271.5256.1734.","journal-title":"Science (1979)"},{"key":"755_CR5","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293\u20137. https:\/\/doi.org\/10.1073\/pnas.192461099.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/med.21765","volume":"41","author":"H Sadeghi Rad","year":"2021","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O\u2019Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41:1474\u201398. https:\/\/doi.org\/10.1002\/med.21765.","journal-title":"Med Res Rev"},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","volume":"71","author":"F Cameron","year":"2011","unstructured":"Cameron F, Whiteside G, Perry C. Ipilimumab. Drugs. 2011;71:1093\u2013104. https:\/\/doi.org\/10.2165\/11594010-000000000-00000.","journal-title":"Drugs"},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMOA1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. https:\/\/doi.org\/10.1056\/NEJMOA1003466.","journal-title":"N Engl J Med"},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma. N Engl J Med. 2015;373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"key":"755_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051145","volume":"14","author":"C Li","year":"2022","unstructured":"Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors\u2014associated cardiotoxicity. Cancers (Basel). 2022;14:1145. https:\/\/doi.org\/10.3390\/cancers14051145.","journal-title":"Cancers (Basel)"},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/circulationaha.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299\u2013311. https:\/\/doi.org\/10.1161\/circulationaha.120.049981.","journal-title":"Circulation"},{"key":"755_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.759972","author":"E Kushnareva","year":"2022","unstructured":"Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O, Frontiers Media {SA}. Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure. Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2021.759972.","journal-title":"Front Cardiovasc Med"},{"key":"755_CR13","doi-asserted-by":"publisher","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A et al. Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study. Lancet Oncol. Lancet Publishing Group; 2018 [cited 2025 Dec 23];19:1579. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"key":"755_CR15","doi-asserted-by":"publisher","unstructured":"Wei SC, Meijers WC, Axelrod ML, Anang NAAS, Screever EM, Wescott EC, et al. A genetic mouse model recapitulates immune checkpoint inhibitor\u2013associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov . American Association for Cancer Research Inc.; 2021 [cited 2024 Apr 14];11:614\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0856\/333556\/AM\/A-GENETIC-MOUSE-MODEL-RECAPITULATES-IMMUNE","DOI":"10.1158\/2159-8290.CD-20-0856\/333556\/AM\/A-GENETIC-MOUSE-MODEL-RECAPITULATES-IMMUNE"},{"key":"755_CR16","doi-asserted-by":"publisher","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326. https:\/\/doi.org\/10.1038\/s41586-022-05432-3.","DOI":"10.1038\/s41586-022-05432-3"},{"key":"755_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.989431\/BIBTEX","volume":"13","author":"LI Yousif","year":"2022","unstructured":"Yousif LI, Tanja AA, de Boer RA, Teske AJ, Meijers WC. The role of immune checkpoints in cardiovascular disease. Front Pharmacol. 2022;13:989431. https:\/\/doi.org\/10.3389\/FPHAR.2022.989431\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"755_CR18","doi-asserted-by":"publisher","unstructured":"Yousif LI, Screever EM, Versluis D, Aboumsallem JP, Nierkens S, Manintveld OC, et al. Risk factors for immune checkpoint inhibitor\u2013mediated cardiovascular toxicities. Curr Oncol Rep. 2023;25:753. https:\/\/doi.org\/10.1007\/S11912-023-01414-4.","DOI":"10.1007\/S11912-023-01414-4"},{"key":"755_CR19","doi-asserted-by":"publisher","unstructured":"van den Berg PF, Bracun V, Noordman M, van der Meer P, Shi C, Oosting SF, et al. Elevations of cardiac troponin in patients receiving immune checkpoint inhibitors: data from a prospective study. JACC: Advances. 2024. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101375.","DOI":"10.1016\/j.jacadv.2024.101375"},{"key":"755_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107458","volume":"209","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang L, Guo H, Kong S, Li W, He Q, et al. The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells. Pharmacol Res. 2024;209:107458. https:\/\/doi.org\/10.1016\/j.phrs.2024.107458.","journal-title":"Pharmacol Res"},{"key":"755_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.681320","volume":"12","author":"JB Lee","year":"2021","unstructured":"Lee JB, Ha S-J, Kim HR. Clinical insights into novel immune checkpoint inhibitors. Front Pharmacol. 2021;12:681320. https:\/\/doi.org\/10.3389\/fphar.2021.681320.","journal-title":"Front Pharmacol"},{"key":"755_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1148536","volume":"318","author":"AC Anderson","year":"2007","unstructured":"Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318:1141\u20133. https:\/\/doi.org\/10.1126\/science.1148536.","journal-title":"Science"},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.21470\/1678-9741-2020-0509","volume":"37","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhan F, Liu H. Expression level and significance of Tim-3 in CD4\u2009+\u2009T lymphocytes in peripheral blood of patients with coronary heart disease. Braz J Cardiovasc Surg. 2022;37:350\u20135. https:\/\/doi.org\/10.21470\/1678-9741-2020-0509.","journal-title":"Braz J Cardiovasc Surg"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2012.02.009","volume":"222","author":"N Hou","year":"2012","unstructured":"Hou N, Zhao D, Liu Y, Gao L, Liang X, Liu X, et al. Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis. Atherosclerosis. 2012;222:67\u201373. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.02.009.","journal-title":"Atherosclerosis"},{"key":"755_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03823-z","volume":"23","author":"Q Wang","year":"2023","unstructured":"Wang Q, Liu G, Teng Y, Feng X, Chen Z, Wang F, et al. Diagnostic value of peripheral TiM-3, NT proBNP, and Sestrin2 testing in left-to-right shunt congenital heart disease with heart failure. BMC Pediatr. 2023;23:7. https:\/\/doi.org\/10.1186\/s12887-022-03823-z.","journal-title":"BMC Pediatr"},{"key":"755_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.933532","author":"X Meng","year":"2022","unstructured":"Meng X, Xia G, Zhang L, Xu C, Chen Z. T cell immunoglobulin and mucin domain-containing protein 3 is highly expressed in patients with acute decompensated heart failure and predicts mid-term prognosis. Front Cardiovasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.933532.","journal-title":"Front Cardiovasc Med"},{"key":"755_CR27","doi-asserted-by":"publisher","unstructured":"Screever EM, Yousif LIE, Moslehi JJ, Salem JE, Voors AA, Sillj\u00e9 HHW, et al. Circulating immune checkpoints predict heart failure outcomes. ESC Heart Fail. 2023;10:2330\u20137. https:\/\/doi.org\/10.1002\/EHF2.14304.","DOI":"10.1002\/EHF2.14304"},{"issue":"1","key":"755_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/J.0105-2896.2010.00903.X","volume":"235","author":"GJ Freeman","year":"2010","unstructured":"Freeman GJ, Casasnovas JM, Umetsu DT, Dekruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235(1):172\u201389. https:\/\/doi.org\/10.1111\/J.0105-2896.2010.00903.X.","journal-title":"Immunol Rev"},{"key":"755_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35754-0","volume":"8","author":"AK Gandhi","year":"2018","unstructured":"Gandhi AK, Kim WM, Sun Z-Y, Huang Y-H, Bonsor DA, Sundberg EJ, et al. High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3. Sci Rep. 2018;8:17512. https:\/\/doi.org\/10.1038\/s41598-018-35754-0.","journal-title":"Sci Rep"},{"issue":"3","key":"755_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2019","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2019;20(3):173\u201385. https:\/\/doi.org\/10.1038\/s41577-019-0224-6.","journal-title":"Nat Rev Immunol"},{"key":"755_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57:206\u201322. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010.","journal-title":"Immunity"},{"key":"755_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245\u201352. https:\/\/doi.org\/10.1038\/ni1271.","journal-title":"Nat Immunol"},{"issue":"2","key":"755_CR33","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4049\/JIMMUNOL.1302663","volume":"192","author":"KL Clayton","year":"2014","unstructured":"Clayton KL, Haaland MS, Douglas-Vail MB, Mujib S, Chew GM, Ndhlovu LC, et al. T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol. 2014;192(2):782\u201391. https:\/\/doi.org\/10.4049\/JIMMUNOL.1302663.","journal-title":"J Immunol"},{"key":"755_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/415536a","volume":"415","author":"L Monney","year":"2002","unstructured":"Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536\u201341. https:\/\/doi.org\/10.1038\/415536a.","journal-title":"Nature"},{"key":"755_CR35","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nm.2871","volume":"18","author":"M Rangachari","year":"2012","unstructured":"Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 Protects T cell Responses by Repressing Tim-3-Mediated Exhaustion and Death. Nat Med. 2012;18:1394\u2013400. https:\/\/doi.org\/10.1038\/nm.2871.","journal-title":"Nat Med"},{"key":"755_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/S11033-025-10729-3","author":"A Rezabakhsh","year":"2025","unstructured":"Rezabakhsh A, Safaei N, Nabavi SM, Roosta Y, Giampieri F, Battino M. Anti-atherogenic immune checkpoint TIM-3 as a promising pharmacologic target toward ischemic heart diseases: a prospective review. Mol Biol Rep. 2025. https:\/\/doi.org\/10.1007\/S11033-025-10729-3.","journal-title":"Mol Biol Rep"},{"key":"755_CR37","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1128\/MCB.05297-11","volume":"31","author":"J Lee","year":"2011","unstructured":"Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways \u25bf. Mol Cell Biol. 2011;31:3963\u201374. https:\/\/doi.org\/10.1128\/MCB.05297-11.","journal-title":"Mol Cell Biol"},{"key":"755_CR38","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1128\/MCB.01983-06","volume":"27","author":"D Davidson","year":"2007","unstructured":"Davidson D, Schraven B, Veillette A. PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes. Mol Cell Biol. 2007;27:1960\u201373. https:\/\/doi.org\/10.1128\/MCB.01983-06.","journal-title":"Mol Cell Biol"},{"key":"755_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2021.04.011","volume":"510","author":"S Kandel","year":"2021","unstructured":"Kandel S, Adhikary P, Li G, Cheng K. The TIM3\/Gal9 signaling pathway: an emerging target for cancer immunotherapy. Cancer Lett. 2021;510:67\u201378. https:\/\/doi.org\/10.1016\/j.canlet.2021.04.011.","journal-title":"Cancer Lett"},{"issue":"7534","key":"755_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature13848","volume":"517","author":"YH Huang","year":"2014","unstructured":"Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014;517(7534):386\u201390. https:\/\/doi.org\/10.1038\/nature13848.","journal-title":"Nature"},{"key":"755_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.clim.2009.09.012","volume":"134","author":"X Li","year":"2010","unstructured":"Li X, Chen G, Li Y, Wang R, Wang L, Lin Z, et al. Involvement of T cell Ig mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease. Clin Immunol. 2010;134:169\u201377. https:\/\/doi.org\/10.1016\/j.clim.2009.09.012.","journal-title":"Clin Immunol"},{"key":"755_CR42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni987","volume":"4","author":"A S\u00e1nchez-Fueyo","year":"2003","unstructured":"S\u00e1nchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, et al. Tim-3 inhibits T helper type 1\u2013mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4:1093\u2013101. https:\/\/doi.org\/10.1038\/ni987.","journal-title":"Nat Immunol"},{"key":"755_CR43","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.4049\/jimmunol.180.7.4409","volume":"180","author":"L Yang","year":"2008","unstructured":"Yang L, Anderson DE, Kuchroo J, Hafler DA. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008;180:4409\u201314. https:\/\/doi.org\/10.4049\/jimmunol.180.7.4409.","journal-title":"J Immunol"},{"key":"755_CR44","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1084\/jem.20060210","volume":"203","author":"K Koguchi","year":"2006","unstructured":"Koguchi K, Anderson DE, Yang L, O\u2019Connor KC, Kuchroo VK, Hafler DA. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006;203:1413\u20138. https:\/\/doi.org\/10.1084\/jem.20060210.","journal-title":"J Exp Med"},{"key":"755_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clim.2012.09.001","volume":"145","author":"F Shi","year":"2012","unstructured":"Shi F, Guo X, Jiang X, Zhou P, Xiao Y, Zhou T, et al. Dysregulated Tim-3 expression and its correlation with imbalanced CD4 helper T cell function in ulcerative colitis. Clin Immunol. 2012;145:230\u201340. https:\/\/doi.org\/10.1016\/j.clim.2012.09.001.","journal-title":"Clin Immunol"},{"key":"755_CR46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2340\/00015555-1285","volume":"92","author":"Y Kanai","year":"2012","unstructured":"Kanai Y, Satoh T, Igawa K, Yokozeki H. Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis. Acta Derm Venereol. 2012;92:367\u201371. https:\/\/doi.org\/10.2340\/00015555-1285.","journal-title":"Acta Derm Venereol"},{"key":"755_CR47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clim.2010.07.012","volume":"137","author":"Y Liu","year":"2010","unstructured":"Liu Y, Shu Q, Gao L, Hou N, Zhao D, Liu X, et al. Increased Tim-3 expression on peripheral lymphocytes from patients with rheumatoid arthritis negatively correlates with disease activity. Clin Immunol. 2010;137:288\u201395. https:\/\/doi.org\/10.1016\/j.clim.2010.07.012.","journal-title":"Clin Immunol"},{"key":"755_CR48","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1042\/BCJ20210425","volume":"478","author":"CM Smith","year":"2021","unstructured":"Smith CM, Li A, Krishnamurthy N, Lemmon MA. Phosphatidylserine binding directly regulates TIM-3 function. Biochem J. 2021;478:3331\u201349. https:\/\/doi.org\/10.1042\/BCJ20210425.","journal-title":"Biochem J"},{"key":"755_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aba0717","volume":"14","author":"S Kataoka","year":"2021","unstructured":"Kataoka S, Manandhar P, Lee J, Workman CJ, Banerjee H, Szymczak-Workman AL, et al. The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse. Sci Signal. 2021;14:eaba0717. https:\/\/doi.org\/10.1126\/scisignal.aba0717.","journal-title":"Sci Signal"},{"key":"755_CR50","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1073\/pnas.1712107115","volume":"115","author":"L Avery","year":"2018","unstructured":"Avery L, Filderman J, Szymczak-Workman AL, Kane LP. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc Natl Acad Sci U S A. 2018;115:2455\u201360. https:\/\/doi.org\/10.1073\/pnas.1712107115.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"755_CR51","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.4049\/jimmunol.1302290","volume":"192","author":"JV Gorman","year":"2014","unstructured":"Gorman JV, Starbeck-Miller G, Pham N-LL, Traver GL, Rothman PB, Harty JT, et al. Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection. J Immunol. 2014;192:3133\u201342. https:\/\/doi.org\/10.4049\/jimmunol.1302290.","journal-title":"J Immunol"},{"key":"755_CR52","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41423-020-00575-7","volume":"18","author":"Y Zhai","year":"2021","unstructured":"Zhai Y, Celis-Gutierrez J, Voisinne G, Mori D, Girard L, Burlet-Schiltz O, et al. Opposing regulatory functions of the TIM3 (HAVCR2) signalosome in primary effector T cells as revealed by quantitative interactomics. Cell Mol Immunol. 2021;18:1581\u20133. https:\/\/doi.org\/10.1038\/s41423-020-00575-7.","journal-title":"Cell Mol Immunol"},{"key":"755_CR53","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.4049\/JIMMUNOL.0903478","volume":"184","author":"S Takamura","year":"2010","unstructured":"Takamura S, Tsuji-Kawahara S, Yagita H, Akiba H, Sakamoto M, Chikaishi T, et al. Premature terminal exhaustion of Friend virus-specific effector CD8\u2009+\u2009T cells by rapid induction of multiple inhibitory receptors. J Immunol. 2010;184:4696\u2013707. https:\/\/doi.org\/10.4049\/JIMMUNOL.0903478.","journal-title":"J Immunol"},{"key":"755_CR54","doi-asserted-by":"publisher","first-page":"14733","DOI":"10.1073\/pnas.1009731107","volume":"107","author":"H-T Jin","year":"2010","unstructured":"Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010;107:14733\u20138. https:\/\/doi.org\/10.1073\/pnas.1009731107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"755_CR55","doi-asserted-by":"publisher","first-page":"9122","DOI":"10.1128\/JVI.00639-09","volume":"83","author":"L Golden-Mason","year":"2009","unstructured":"Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in Hepatitis C virus infection and its blockade rescues dysfunctional CD4\u2009+\u2009and CD8\u2009+\u2009T cells. J Virol. 2009;83:9122\u201330. https:\/\/doi.org\/10.1128\/JVI.00639-09.","journal-title":"J Virol"},{"key":"755_CR56","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1084\/jem.20081398","volume":"205","author":"RB Jones","year":"2008","unstructured":"Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763\u201379. https:\/\/doi.org\/10.1084\/jem.20081398.","journal-title":"J Exp Med"},{"key":"755_CR57","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","volume":"193","author":"RL Ferris","year":"2014","unstructured":"Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol. 2014;193:1525\u201330. https:\/\/doi.org\/10.4049\/jimmunol.1400557.","journal-title":"J Immunol"},{"key":"755_CR58","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1002\/eji.201344392","volume":"44","author":"A-S Gautron","year":"2014","unstructured":"Gautron A-S, Dominguez-Villar M, de Marcken M, Hafler DA. Enhanced suppressor function of TIM-3\u2009+\u2009FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703\u201311. https:\/\/doi.org\/10.1002\/eji.201344392.","journal-title":"Eur J Immunol"},{"key":"755_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030676","volume":"7","author":"X Gao","year":"2012","unstructured":"Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One. 2012;7:e30676. https:\/\/doi.org\/10.1371\/journal.pone.0030676.","journal-title":"PLoS One"},{"key":"755_CR60","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23849","volume":"2","author":"K Sakuishi","year":"2013","unstructured":"Sakuishi K, Ngiow SF, Sullivan JM, Teng MWL, Kuchroo VK, Smyth MJ, et al. TIM3\u2009+\u2009FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2013;2:e23849. https:\/\/doi.org\/10.4161\/onci.23849.","journal-title":"Oncoimmunology"},{"key":"755_CR61","doi-asserted-by":"publisher","first-page":"109699","DOI":"10.1016\/j.celrep.2021.109699","volume":"36","author":"H Banerjee","year":"2021","unstructured":"Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath KV, Chandran UR, et al. Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021;36:109699. https:\/\/doi.org\/10.1016\/j.celrep.2021.109699.","journal-title":"Cell Rep"},{"key":"755_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","volume":"127","author":"M Seki","year":"2008","unstructured":"Seki M, Oomizu S, Sakata K, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127:78\u201388. https:\/\/doi.org\/10.1016\/j.clim.2008.01.006.","journal-title":"Clin Immunol"},{"key":"755_CR63","doi-asserted-by":"publisher","first-page":"e1000882","DOI":"10.1371\/journal.ppat.1000882","volume":"6","author":"S Sehrawat","year":"2010","unstructured":"Sehrawat S, Reddy PBJ, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT. Galectin-9\/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8\u2009+\u2009T Cell Response. PLoS Pathog. 2010;6:e1000882. https:\/\/doi.org\/10.1371\/journal.ppat.1000882.","journal-title":"PLoS Pathog"},{"key":"755_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058006","volume":"8","author":"J Yan","year":"2013","unstructured":"Yan J, Zhang Y, Zhang J-P, Liang J, Li L, Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLoS One. 2013;8:e58006. https:\/\/doi.org\/10.1371\/journal.pone.0058006.","journal-title":"PLoS One"},{"key":"755_CR65","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","volume":"119","author":"LC Ndhlovu","year":"2012","unstructured":"Ndhlovu LC, Lopez-Verg\u00e8s S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119:3734\u201343. https:\/\/doi.org\/10.1182\/blood-2011-11-392951.","journal-title":"Blood"},{"key":"755_CR66","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/BLOOD-2011-06-360321","volume":"119","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, Lenvik TR, McCullar V, Felices M, O\u2019Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012;119:3064\u201372. https:\/\/doi.org\/10.1182\/BLOOD-2011-06-360321.","journal-title":"Blood"},{"key":"755_CR67","doi-asserted-by":"publisher","first-page":"12414","DOI":"10.4049\/jimmunol.200.Supp.124.14","volume":"200","author":"AM Farkas","year":"2018","unstructured":"Farkas AM, Audenet F, Anastos H, Galsky M, Sfakianos J, Bhardwaj N. Tim-3 and TIGIT mark natural killer cells susceptible to effector dysfunction in human bladder cancer. J Immunol. 2018;200:12414. https:\/\/doi.org\/10.4049\/jimmunol.200.Supp.124.14.","journal-title":"J Immunol"},{"key":"755_CR68","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.intimp.2015.09.017","volume":"29","author":"L Xu","year":"2015","unstructured":"Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, et al. Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29:635\u201341. https:\/\/doi.org\/10.1016\/j.intimp.2015.09.017.","journal-title":"Int Immunopharmacol"},{"key":"755_CR69","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3109\/08820139.2015.1052145","volume":"44","author":"Z Wang","year":"2015","unstructured":"Wang Z, Zhu J, Gu H, Yuan Y, Zhang B, Zhu D, et al. The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer. Immunol Invest. 2015;44:578\u201389. https:\/\/doi.org\/10.3109\/08820139.2015.1052145.","journal-title":"Immunol Invest"},{"key":"755_CR70","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171\/466993\/","volume":"2","author":"IP Da Silva","year":"2014","unstructured":"Da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res.\u00a02(5):410\u201322.\u00a0https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0171","journal-title":"Cancer Immunol Res"},{"key":"755_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-019-1917-0","volume":"17","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Li Y, Lian J, Yang H, Li F, Zhao S, et al. TNF-\u03b1-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer. J Transl Med. 2019;17:165. https:\/\/doi.org\/10.1186\/s12967-019-1917-0.","journal-title":"J Transl Med"},{"key":"755_CR72","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1172\/JCI45816","volume":"121","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121:3609\u201322. https:\/\/doi.org\/10.1172\/JCI45816.","journal-title":"J Clin Invest"},{"key":"755_CR73","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.yexcr.2018.09.013","volume":"372","author":"W Zhang","year":"2018","unstructured":"Zhang W, Feng H, Chen Q, Lu X, Ge J. The functional potency of natural killer cells in response to IL-2\/IL-15\/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer. Exp Cell Res. 2018;372:92\u20138. https:\/\/doi.org\/10.1016\/j.yexcr.2018.09.013.","journal-title":"Exp Cell Res"},{"key":"755_CR74","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-19-2332","volume":"80","author":"S Tan","year":"2020","unstructured":"Tan S, Xu Y, Wang Z, Wang T, Du X, Song X, et al. Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling. Cancer Res. 2020;80:1130\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2332.","journal-title":"Cancer Res"},{"key":"755_CR75","doi-asserted-by":"publisher","first-page":"1889822","DOI":"10.1080\/2162402X.2021.1889822","volume":"10","author":"J Rakova","year":"2021","unstructured":"Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, et al. TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. Oncoimmunology. 2021;10:1889822. https:\/\/doi.org\/10.1080\/2162402X.2021.1889822.","journal-title":"Oncoimmunology"},{"key":"755_CR76","doi-asserted-by":"publisher","first-page":"eabm0631","DOI":"10.1126\/sciimmunol.abm0631","volume":"7","author":"R Tang","year":"2022","unstructured":"Tang R, Acharya N, Subramanian A, Purohit V, Tabaka M, Hou Y, et al. Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Sci Immunol. 2022;7:eabm0631. https:\/\/doi.org\/10.1126\/sciimmunol.abm0631.","journal-title":"Sci Immunol"},{"key":"755_CR77","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","volume":"33","author":"\u00c1 de Mingo Pulido","year":"2018","unstructured":"de Mingo Pulido \u00c1, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, et al. TIM-3 regulates CD103\u2009+\u2009dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018;33:60\u2013e746. https:\/\/doi.org\/10.1016\/j.ccell.2017.11.019.","journal-title":"Cancer Cell"},{"key":"755_CR78","doi-asserted-by":"publisher","unstructured":"Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113:3821\u201330. https:\/\/doi.org\/10.1182\/BLOOD-2008-10-185884.","DOI":"10.1182\/BLOOD-2008-10-185884"},{"key":"755_CR79","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/NI.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol Nat Immunol. 2012;13:832\u201342. https:\/\/doi.org\/10.1038\/NI.2376. [cited 2024 Oct 2];.","journal-title":"Nat Immunol Nat Immunol"},{"key":"755_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon KO, Tabaka M, Schramm MA, Xiao S, Tang R, Dionne D, et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595:101\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03626-9.","journal-title":"Nature"},{"key":"755_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194821","volume":"13","author":"CC Stempin","year":"2021","unstructured":"Stempin CC, Geysels RC, Park S, Palacios LM, Volpini X, Motran CC, et al. Secreted factors by anaplastic thyroid cancer cells induce tumor-promoting M2-like macrophage polarization through a TIM3-dependent mechanism. Cancers (Basel). 2021;13:4821. https:\/\/doi.org\/10.3390\/cancers13194821.","journal-title":"Cancers (Basel)"},{"key":"755_CR82","doi-asserted-by":"publisher","unstructured":"DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim Y-L, Lee H-H, et al. T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol. 2010;184(4):1918\u201330. https:\/\/doi.org\/10.4049\/JIMMUNOL.0903059.","DOI":"10.4049\/JIMMUNOL.0903059"},{"key":"755_CR83","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1189\/JLB.1010591","volume":"91","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Moorman JP, et al. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14\u2009+\u2009monocytes. J Leukoc Biol J Leukoc Biol. 2012;91:189\u201396. https:\/\/doi.org\/10.1189\/JLB.1010591. [cited 2024 Oct 2];.","journal-title":"J Leukoc Biol J Leukoc Biol"},{"key":"755_CR84","doi-asserted-by":"publisher","unstructured":"Yang X, Jiang X, Chen G, Xiao Y, Geng S, Kang C, et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol. 2013;190:2068\u201379. https:\/\/doi.org\/10.4049\/JIMMUNOL.1202661.","DOI":"10.4049\/JIMMUNOL.1202661"},{"key":"755_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072488","volume":"8","author":"CJ Ma","year":"2013","unstructured":"Ma CJ, Li GY, Cheng YQ, Wang JM, Ying RS, Shi L, et al. Cis association of galectin-9 with Tim-3 differentially regulates IL-12\/IL-23 expressions in monocytes via TLR signaling. PLoS One. 2013;8:e72488. https:\/\/doi.org\/10.1371\/journal.pone.0072488.","journal-title":"PLoS One"},{"key":"755_CR86","doi-asserted-by":"publisher","first-page":"eabl5165","DOI":"10.1126\/sciadv.abl5165","volume":"8","author":"X Ni","year":"2022","unstructured":"Ni X, Wu W, Sun X, Ma J, Yu Z, He X, et al. Interrogating glioma-M2 macrophage interactions identifies Gal-9\/Tim-3 as a viable target against PTEN-null glioblastoma. Sci Adv. 2022;8:eabl5165. https:\/\/doi.org\/10.1126\/sciadv.abl5165.","journal-title":"Sci Adv"},{"key":"755_CR87","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.arcmed.2020.10.018","volume":"52","author":"Z Cheng","year":"2021","unstructured":"Cheng Z, Wang L, Wu C, Huang L, Ruan Y, Xue W. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3. Arch Med Res. 2021;52:200\u201310. https:\/\/doi.org\/10.1016\/j.arcmed.2020.10.018.","journal-title":"Arch Med Res"},{"key":"755_CR88","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","volume":"64","author":"W Yan","year":"2015","unstructured":"Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, et al. Tim-3 fosters HCC development by enhancing TGF-\u03b2-mediated alternative activation of macrophages. Gut. 2015;64:1593\u2013604. https:\/\/doi.org\/10.1136\/gutjnl-2014-307671.","journal-title":"Gut"},{"key":"755_CR89","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1211219","author":"X Jiang","year":"2016","unstructured":"Jiang X, Zhou T, Xiao Y, Yu J, Dou S, Chen G, et al. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. Oncoimmunology. 2016. https:\/\/doi.org\/10.1080\/2162402X.2016.1211219.","journal-title":"Oncoimmunology"},{"key":"755_CR90","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/J.CLIM.2015.07.008","volume":"160","author":"X Jiang","year":"2015","unstructured":"Jiang X, Yu J, Shi Q, Xiao Y, Wang W, Chen G, et al. Tim-3 promotes intestinal homeostasis in DSS colitis by inhibiting M1 polarization of macrophages. Clin Immunol. 2015;160:328\u201335. https:\/\/doi.org\/10.1016\/J.CLIM.2015.07.008.","journal-title":"Clin Immunol"},{"key":"755_CR91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmet.2019.02.007","volume":"23","author":"H Yang","year":"2019","unstructured":"Yang H, Xie T, Li D, Du X, Wang T, Li C, et al. Tim-3 aggravates podocyte injury in diabetic nephropathy by promoting macrophage activation via the NF-\u03baB\/TNF-\u03b1 pathway. Mol Metab. 2019;23:24\u201336. https:\/\/doi.org\/10.1016\/j.molmet.2019.02.007.","journal-title":"Mol Metab"},{"key":"755_CR92","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1084\/JEM.20150388","volume":"212","author":"BL Phong","year":"2015","unstructured":"Phong BL, Avery L, Sumpter TL, Gorman JV, Watkins SC, Colgan JD, et al. Tim-3 enhances Fc\u03b5RI-proximal signaling to modulate mast cell activation. J Exp Med. 2015;212:2289\u2013304. https:\/\/doi.org\/10.1084\/JEM.20150388.","journal-title":"J Exp Med"},{"key":"755_CR93","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1182\/blood-2006-11-058800","volume":"110","author":"S Nakae","year":"2007","unstructured":"Nakae S, Iikura M, Suto H, Akiba H, Umetsu DT, DeKruyff RH, et al. TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood. 2007;110:2565\u20138. https:\/\/doi.org\/10.1182\/blood-2006-11-058800.","journal-title":"Blood"},{"key":"755_CR94","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/sj.jid.5700616","volume":"127","author":"Z Wiener","year":"2007","unstructured":"Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, et al. TIM-3 Is Expressed in Melanoma Cells and Is Upregulated in TGF-Beta Stimulated Mast Cells. J Invest Dermatology. 2007;127:906\u201314. https:\/\/doi.org\/10.1038\/sj.jid.5700616.","journal-title":"J Invest Dermatology"},{"key":"755_CR95","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4110\/in.2012.12.5.207","volume":"12","author":"JS Kim","year":"2012","unstructured":"Kim JS, Shin D-C, Woo M-Y, Kwon M-H, Kim K, Park S. T cell immunoglobulin mucin domain (TIM)-3 promoter activity in a human mast cell line. Immune Netw. 2012;12:207\u201312. https:\/\/doi.org\/10.4110\/in.2012.12.5.207.","journal-title":"Immune Netw"},{"key":"755_CR96","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.molimm.2011.05.004","volume":"48","author":"S-J Yoon","year":"2011","unstructured":"Yoon S-J, Lee MJ, Shin D-C, Kim JS, Chwae Y-J, Kwon M-H, et al. Activation of mitogen activated protein kinase-Erk kinase (MEK) increases T cell immunoglobulin mucin domain-3 (TIM-3) transcription in human T lymphocytes and a human mast cell line. Mol Immunol. 2011;48:1778\u201383. https:\/\/doi.org\/10.1016\/j.molimm.2011.05.004.","journal-title":"Mol Immunol"},{"key":"755_CR97","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","volume":"619","author":"L Bod","year":"2023","unstructured":"Bod L, Kye Y-C, Shi J, Triglia ET, Schnell A, Fessler J, et al. <article-title update=\"modified\" original=\"B-cell specific checkpoint molecules that regulate anti-tumor immunity\">B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023;619:348\u201356. https:\/\/doi.org\/10.1038\/s41586-023-06231-0.","journal-title":"Nature"},{"key":"755_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128523","volume":"10","author":"M-K Qiu","year":"2015","unstructured":"Qiu M-K, Wang S-C, Dai Y-X, Wang S-Q, Ou J-M, Quan Z-W. PD-1 and Tim-3 pathways regulate CD8\u2009+\u2009T cells function in atherosclerosis. PLoS One. 2015;10:e0128523. https:\/\/doi.org\/10.1371\/journal.pone.0128523.","journal-title":"PLoS One"},{"key":"755_CR99","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3892\/mmr.2020.11167","volume":"22","author":"C Lian","year":"2020","unstructured":"Lian C, Wang Z, Qiu J, Jiang B, Lv J, He R, et al. TIM-3 inhibits PDGF-BB-induced atherogenic responses in human artery vascular smooth muscle cells. Mol Med Rep. 2020;22:886\u201394. https:\/\/doi.org\/10.3892\/mmr.2020.11167.","journal-title":"Mol Med Rep"},{"key":"755_CR100","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1161\/ATVBAHA.113.301879","volume":"33","author":"AC Foks","year":"2013","unstructured":"Foks AC, Ran IA, Wasserman L, Frodermann V, ter Borg MND, de Jager SCA, et al. T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:2558\u201365. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301879.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"755_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568431","volume":"16","author":"RD Reitsema","year":"2025","unstructured":"Reitsema RD, Kurt S, Rangel I, Hjelmqvist H, Dreifaldt M, Sirsj\u00f6 A, et al. Patients with peripheral artery disease demonstrate altered expression of soluble and membrane-bound immune checkpoints. Front Immunol. 2025;16:1568431. https:\/\/doi.org\/10.3389\/fimmu.2025.1568431.","journal-title":"Front Immunol"},{"key":"755_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.900334","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Jiang S, Li J, Yin M, Yan F, Chen Y, et al. Phenotypic changes of peripheral \u03b3\u03b4 T cell and its subsets in patients with coronary artery disease. Front Immunol. 2022;13:900334. https:\/\/doi.org\/10.3389\/fimmu.2022.900334.","journal-title":"Front Immunol"},{"key":"755_CR103","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2017.12.050","volume":"821","author":"N Zhang","year":"2018","unstructured":"Zhang N, Zhang M, Liu R-T, Zhang P, Yang C-L, Yue L-T, et al. Statins reduce the expressions of Tim-3 on NK cells and NKT cells in atherosclerosis. Eur J Pharmacol. 2018;821:49\u201356. https:\/\/doi.org\/10.1016\/j.ejphar.2017.12.050.","journal-title":"Eur J Pharmacol"},{"key":"755_CR104","doi-asserted-by":"publisher","first-page":"61001","DOI":"10.18632\/oncotarget.17720","volume":"8","author":"M-K Qiu","year":"2017","unstructured":"Qiu M-K, Wang S-C, Tang Y, Pan C, Wang Y, Wang S-Q, et al. Tim-3 inhibits low-density lipoprotein-induced atherogenic responses in human umbilical vein endothelial cells. Oncotarget. 2017;8:61001\u201310. https:\/\/doi.org\/10.18632\/oncotarget.17720.","journal-title":"Oncotarget"},{"key":"755_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01685-x","volume":"44","author":"N Pernaa","year":"2024","unstructured":"Pernaa N, Vakkuri A, Arvonen M, Kuismin O, Santaniemi W, Glumoff V, et al. Germline HAVCR2\/TIM-3 checkpoint inhibitor receptor deficiency in recurrent autoinflammatory myocarditis. J Clin Immunol. 2024;44:81. https:\/\/doi.org\/10.1007\/s10875-024-01685-x.","journal-title":"J Clin Immunol"},{"key":"755_CR106","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.4049\/jimmunol.176.11.6411","volume":"176","author":"S Frisancho-Kiss","year":"2006","unstructured":"Frisancho-Kiss S, Nyland JF, Davis SE, Barrett MA, Gatewood SJL, Njoku DB, et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol. 2006;176:6411\u20135. https:\/\/doi.org\/10.4049\/jimmunol.176.11.6411.","journal-title":"J Immunol"},{"key":"755_CR107","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbi.2008.12.002","volume":"23","author":"S Frisancho-Kiss","year":"2009","unstructured":"Frisancho-Kiss S, Coronado MJ, Frisancho JA, Lau VM, Rose NR, Klein SL, et al. Gonadectomy of male BALB\/c mice increases Tim-3\u2009+\u2009alternatively activated M2 macrophages, Tim-3\u2009+\u2009T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun. 2009;23:649\u201357. https:\/\/doi.org\/10.1016\/j.bbi.2008.12.002.","journal-title":"Brain Behav Immun"},{"key":"755_CR108","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.4049\/jimmunol.178.11.6710","volume":"178","author":"S Frisancho-Kiss","year":"2007","unstructured":"Frisancho-Kiss S, Davis SE, Nyland JF, Frisancho JA, Cihakova D, Barrett MA, et al. Cutting edge: Cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178:6710\u20134. https:\/\/doi.org\/10.4049\/jimmunol.178.11.6710.","journal-title":"J Immunol"},{"key":"755_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S44325-025-00061-X","volume":"2","author":"LI Yousif","year":"2025","unstructured":"Yousif LI, Sijtema AG, Appels Y, Screever EM, van Blokland IV, Oelen R, et al. The immune checkpoint TIM-3\/HMGB-1 axis in myocardial infarction. npj Cardiovascular Health 2025 2:1. 2025;2:1\u201312. https:\/\/doi.org\/10.1038\/S44325-025-00061-X.","journal-title":"npj Cardiovascular Health 2025 2:1"},{"key":"755_CR110","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1007\/s11010-025-05277-0","volume":"480","author":"J Huang","year":"2025","unstructured":"Huang J, Hu W, Xiong H, Zhou Y, Cao F, Ding C, et al. Cardiomyocyte-derived galectin-9 induces macrophage M2 polarization via the TIM3 pathway to attenuate myocardial remodeling post-myocardial infarction. Mol Cell Biochem. 2025;480:4809\u201327. https:\/\/doi.org\/10.1007\/s11010-025-05277-0.","journal-title":"Mol Cell Biochem"},{"key":"755_CR111","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1111\/CTS.13630","volume":"16","author":"A Wahid","year":"2023","unstructured":"Wahid A, Wen J, Yang Q, Zhang Z, Zhao X, Tang X. Serum HMGB1 is a biomarker for acute myocardial infarction with or without heart failure. Clin Transl Sci. 2023;16:2299\u2013309. https:\/\/doi.org\/10.1111\/CTS.13630.","journal-title":"Clin Transl Sci"},{"key":"755_CR112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00018-018-2930-9","volume":"76","author":"A Raucci","year":"2018","unstructured":"Raucci A, Di Maggio S, Scavello F, D\u2019Ambrosio A, Bianchi ME, Capogrossi MC. The Janus face of HMGB1 in heart disease: a necessary update. Cell Mol Life Sci. 2018;76:211\u201329. https:\/\/doi.org\/10.1007\/s00018-018-2930-9.","journal-title":"Cell Mol Life Sci"},{"key":"755_CR113","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jaccao.2025.05.014","volume":"7","author":"RA de Boer","year":"2025","unstructured":"de Boer RA, Yousif LI, Aboumsallem JP, Meijers WC. Current insights in bidirectional cardio-oncology: heart failure driving cancer: JACC: cardiooncology short-form primer. JACC CardioOncol. 2025;7:518\u201322. https:\/\/doi.org\/10.1016\/j.jaccao.2025.05.014.","journal-title":"JACC CardioOncol"},{"key":"755_CR114","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41440-024-02015-9","volume":"48","author":"M Kuwabara","year":"2025","unstructured":"Kuwabara M. The interplay between cancer and cardiovascular disease. Hypertens Res. 2025;48:1192\u20134. https:\/\/doi.org\/10.1038\/s41440-024-02015-9.","journal-title":"Hypertens Res"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00755-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00755-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:08:25Z","timestamp":1775549305000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00755-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00755-y","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The institution of RAdB has received research grants and\/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk; RAdB has had speaker engagements with and\/or received fees from and\/or served on an advisory board for Abbott, AstraZeneca, NovoNordisk. WCM has received speaker\/ advisory board fees from Daiichi Sankyo, Astellas, Nordic and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}